Impact of bronchiectasis on long-term survival in patients with acute exacerbation of chronic obstructive pulmonary disease

CURRENT STATUS: POSTED

Ying Zhang
Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University

Shu Zhang
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University

Yan-Li Gao
Department of Radiology, Beijing Chao-Yang Hospital, Capital Medical University

Zhen Wang
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University

Xiao-Ning Bu
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University

Ke-Wu Huang
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University

Huan-Zhong Shi
Beijing Chao-Yang Hospital, Capital Medical University

shihuanzhong@sina.com Corresponding Author

Ying-Xiang Lin
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University

DOI:
10.21203/rs.2.10220/v1
Abstract

Background

Only few studies have reported the association between bronchiectasis and mortality in patients with Chronic Obstructive Pulmonary Disease (COPD) and the results were controversial. This study aimed at assessing the prognostic influence of bronchiectasis on COPD patients and comparing differences of prognostic influence of different types of bronchiectasis on COPD patients.

Patients and methods

This study enrolled patients hospitalized for COPD exacerbation between 2013 and 2014. Bronchiectasis was identified on high-resolution computed tomography (HRCT) within 2 years prior to this hospitalization due to COPD exacerbation and Smith score was used to determine the extent of bronchiectasis. Clinical data were obtained from electronic inpatient medical record. The survival data were obtained through telephone follow-up or electronic medical record. Cox regression analysis was used to assess the prognostic influence of bronchiectasis on COPD patients.

Results

748 COPD patients were included in this study. 318 patients were identified to have bronchiectasis. During a median follow-up time of 46 months, 624 COPD patients completed follow-up. There were 210 deaths, 112 of whom were comorbid bronchiectasis patients. Comorbid bronchiectasis patients revealed higher mortality than without bronchiectasis patients in 3 years and the whole follow-up, other than in hospital, 1 year and 2 years. The presence of bronchiectasis and its severity were independently associated with increased mortality of COPD patients. The presence of cystic/varicose bronchiectasis revealed higher mortality than cylindrical bronchiectasis and was independently associated with increased mortality of comorbid bronchiectasis patients.

Conclusions

The presence of bronchiectasis and its severity were independently associated with increased risk of all-cause mortality and mainly affected the long-term mortality of COPD patients. The presence of cystic/varicose bronchiectasis predicted higher death risk of COPD patients.

Introduction
COPD (Chronic Obstructive Pulmonary Disease) is a heterogeneous disease with high morbidity and mortality and its mortality will continue to increase in the coming decades. Therefore, identification of COPD patients at risk for higher mortality is very important. Currently, many variables which are associated with increased mortality of COPD such as severe exacerbations of COPD [1], pulmonary hypertension and weight loss, age, gender [2], some biologic parameters, such as C-reactive protein, neutrophil count, eosinophil count [3], fibrinogen and hypercapnia [4-5], Pseudomonas aeruginosa isolates have been detected [6]. However, these evidences are insufficient to explain the whole picture of COPD death risk. COPD often coexists with other diseases (comorbidities) which may have significant impacts on prognosis of COPD patients. With increasing use of high-resolution computed tomography (HRCT) in assessment of COPD, a high prevalence of previously undiagnosed bronchiectasis was found in COPD patients, ranging from 8.1-69% [7-19]. Some previous studies suggested the presence of bronchiectasis predicted worse outcome of COPD patients [9-11, 13, 15, 20]. Therefore, bronchiectasis was proposed as one of COPD comorbidities by 2014 global initiative for chronic obstructive lung disease (GOLD). Up to now, there have been limited studies related to prognostic impact of bronchiectasis on COPD patients and the results were controversial [7, 11, 13, 21].

Bronchiectasis is described as cylindrical, varicose and cystic types according to morphology [22]. The previous studies reported most of radiological bronchiectasis were cylindrical in COPD population, and a few of bronchiectasis were varicose/cystic [8, 13]. Mao et al found comorbid cylindrical bronchiectasis patients presented higher oxygen partial pressure and moderate dyspnea than comorbid cystic bronchiectasis patients [13]. Another study revealed that there were more frequent mucopurulent sputum and more severe airway obstruction in comorbid cystic/varicose bronchiectasis patients compared with comorbid cylindrical bronchiectasis patients [8]. Therefore, we suspected that whether the presence of cystic/varicose bronchiectasis predicted worse prognosis of COPD patients. Up to now, there has been no study about the relationship between types of bronchiectasis and mortality of COPD patients. In the present study, our main aims were to assess the prognostic influence of the presence of bronchiectasis diagnosed on HRCT within 2 years prior to this
hospitalization due to COPD exacerbation and its severity on COPD patients. In addition, we also compared differences of prognostic influence of different types of bronchiectasis on COPD patients.

Materials And Methods

Study subjects

1148 patients firstly hospitalized for COPD exacerbation at Beijing Chao-Yang Hospital of affiliated hospital of Capital Medical University between January 1, 2013 and December 31, 2014 were identified. COPD was defined by smoking history ≥10 pack-year or/and biomass history ≥10 years and postbronchodilator forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) <70% according to GOLD [23]. Patients who underwent HRCT scans within 2 years prior to first hospitalization due to COPD exacerbation between January 1, 2013 and December 31, 2014 were included in this study. We excluded 400 patients admitted with COPD exacerbation. Excluded patients included: 174 patients with doctor diagnosed bronchiectasis or asthma before COPD; 4 patients with interstitial lung disease; 14 patients with active cancer; 22 patients with history of lobectomy; 1 patient with active tuberculosis; 7 patients with severe lung damage resulting from previous pulmonary tuberculosis (“destroyed lung”); 10 patients with allergic bronchopulmonary aspergillosis (“ABPA”); 125 patients without available HRCT scans; 19 patients with unexplainable HRCT; 24 patients admitted to hospital because of comorbidities rather than COPD exacerbation. Of 1148 COPD patients were initially eligible for the study, 748 COPD patients were included in this study after exclusion. The earliest hospitalization data for patients repeatedly hospitalized for COPD exacerbation between January 2013 and December 2014 were used for analysis.

Lung HRCT analysis

Chest HRCT was performed using a 64-MDCT system (LightSpeed VCT, GE Healthcare). The presence and the extent of radiological bronchiectasis were independently evaluated and interpreted by a radiologist and a respiratory physician who were blind to clinical data of study subjects. If there were differences in the readings, the radiologist and the respiratory physician discussed the case and reached a final consensus. The diagnostic criteria of bronchiectasis were as follows [24]: (1) lack of tapering of bronchia; (2) the internal diameter of the dilated bronchus was greater than that of the
adjacent pulmonary artery; (3) the peripheral bronchus can be seen within the 1 cm of the costal pleural surface or adjacent mediastinal pleural surface. The extent of bronchiectasis was scored according to the scoring system suggested by Smith (0=0%, 1<25%, 2=25-49%, 3=50%-74%, 4≥75%). The lingula was counted as a separate lobe, therefore, each patient may have a maximum score of 24 [22]. If bronchiectasis was identified only in one pulmonary segment, it was not counted, as this may exist in a significant percentage of healthy population [25, 26]. Therefore, COPD patients with a total score of 2 or more were considered as comorbid clinically significant bronchiectasis patients, while those with a score of 0 or 1 were counted as normal. The types of bronchiectasis were defined according to the morphology of bronchiectasis [22].

Clinical variables
Data that were collected from electronic inpatient medical record included age, sex, body mass index; smoking status; clinical outline (Time since onset of symptoms, daily expectoration, history of dyspnea, length of hospital); hospitalization for acute exacerbation of COPD in the previous year; previous history and comorbidities; laboratory blood tests; sputum pathogenic microorganism tests; post-bronchodilator pulmonary function within 1 year prior to this COPD exacerbation.

Follow-up Assessment
The follow-up was completed on March 1, 2018. The endpoint event of this study was all-cause mortality of each patient. Information about death events of COPD patients was obtained by telephone contact with these patients or their relatives or from electronic inpatient medical record. A patient was considered loss of follow-up if we were unable to contact with the patient during the study period. For each patient, the end date of follow-up was the date of death or the last contact of the patient.

Data analysis
Quantitative variables were expressed as mean±standard deviation (SD) and qualitative variables were expressed as absolute numbers and percentages. In the bivariate analysis, Student’s t test was used for comparison of normally distributed data and Mann-Whitney U test was used for comparison
of non-normally distributed data between two groups. The chi-square test was used for comparison of qualitative variables between two groups. Cox’s proportional hazard regression model was used for analysis of independent risk factors of mortality of COPD patients. The following initial factors were examined for the prognostic value of COPD patients: sex, age, smoking history, length of hospitalization, time since onset of symptoms, daily expectoration, hemoglobin, albumin, fibrinogen, presence of PPMs (potential pathogenic microorganisms) in sputum, previous tuberculosis history, pulmonary heart disease, ischemic heart disease, arrhythmias, heart failure, *Pseudomonas aeruginosa* isolates, hospitalization for acute exacerbation of COPD in the previous year, the presence of bronchiectasis, the Smith score of bronchiectasis or bronchiectasis type. Results were expressed as hazard ratio (HR) and 95% confidence interval (CI). Hazard ratios (HRs) were presented in two ways: (1) for comorbid bronchiectasis subjects compared with the absent of bronchiectasis subjects; (2) the quantitative variables “Smith score” instead of the dichotomous variables “presence of bronchiectasis” compared with the absent of bronchiectasis subjects. In addition, Cox’s proportional hazard regression model was also used for the analysis of prognostic influence of different types of bronchiectasis on COPD patients. The forward stepwise method was used and variables with a p value >0.1 were removed from the model. Finally, Kaplan-Meier survival analysis were performed with the log-rank test to compare survival curves between patients with and without bronchiectasis or among absent, cylindrical, varicose/cystic bronchiectasis patients. A p value of <0.05 was considered to be statistically significant. Analyses were performed with SPSS version 23 (SPSS Chicago IL).

**Results**

**Patients**

A total of 748 COPD patients were included in the study. There were 550 (73.5%) males and 198 (26.5%) females. The mean age of all of the COPD patients was 73.06±9.34. There were 587 (78.5%) current or former smokers, and the average pack-years smoked was 41.31±29.21. 69 (9.2%) patients presented a history of pulmonary tuberculosis and received anti-tuberculosis therapy. Radiological bronchiectasis (Smith score ≥2) was diagnosed on HRCT in 318 (42.5%) COPD patients (see Table 1), with the Smith score ranging from 2 to 16 and the average score of bronchiectasis was 4.35±2.35.
The total bronchiectasis score was shown in Figure 1.

Table 1 showed comorbid bronchiectasis patients tended to be male, had lower body mass index, a longer history of exertional dyspnea, greater fibrinogen concentration, more *Pseudomonas aeruginosa* isolates compared with without bronchiectasis patients \( (p<0.05) \). No other significant differences were observed between two groups \( (p>0.05) \).

Table 2 showed baseline lung function comparison between comorbid bronchiectasis patients and without bronchiectasis patients. The comorbid bronchiectasis patients tended to have lower FEV\(_1\)% predicted \( (p=0.013) \) and FEV\(_1\)/FVC% \( (p=0.003) \) compared with without bronchiectasis patients.

**Follow-up and survival analysis**

Of all of the patients, 17 COPD patients died in hospital, 99 COPD patients were not contacted during the follow-up period, the dates of death in 8 patients were not clear and therefore 624 COPD patients were used for survival analysis. The characteristics of COPD patients included and not included in the survival analysis were shown in Supplementary Table A1. There was no difference between two groups other than daily expectoration (see Supplementary Table A1). 210 (33.7%) patients died during a median follow-up time of 46 months. 5 survived less than 30 days, 5 survived less than 90 days, 29 survived less than 1 year, 60 survived less than 2 year, 57 survived less than 3 year after discharge, respectively. Comorbid bronchiectasis patients revealed higher mortality in 3 years after discharge and all follow-up period than without bronchiectasis patients \( (p<0.05) \), while there was no significant difference in hospital, 1 year and 2 years mortality \( (p>0.05) \). During the follow-up period, 145 (69%) patients died from respiratory cause; 20 (9.5%) patients died from cardiovascular diseases; 17 (8.1%) died from cancer; other 28 (13.3%) patients died from other causes. There was no difference in causes of death between two groups \( (p=0.405) \) (see Supplementary Table A2).

Figure 2 showed the significantly different survival curves between comorbid \( (n=272, 112 \text{ death}) \) and without \( (n=352, 98 \text{ death}) \) bronchiectasis patients \( (\text{log-rank test } 11.201, \ p=0.001) \). Multivariate Cox's proportional hazard regression analysis showed bronchiectasis was independently associated with mortality of COPD adjusted for confounding variables \( (\text{HR } 1.504, 95\% \text{ CI}, 1.144-1.978, \ p=0.003) \). Other
variables such as age, length of hospitalization, albumin, hospitalization for acute exacerbation of COPD in the previous year, pulmonary heart disease were also independently associated with mortality of COPD patients in the unadjusted and fully adjusted models (see Table 3). Furthermore, using of Smith score of bronchiectasis instead of the presence of bronchiectasis included in the same model was still independently associated with mortality of COPD patients (HR 1.058, 95%CI, 1.007-1.112, p=0.026) (see Table 4).

The subjects in this study were patients with acute exacerbation of COPD. To minimize the possibility that early death of the patients may be associated with this acute exacerbation, Cox regression analysis was repeatedly evaluated after excluding patients who died in hospital and died within 90 days after discharge and the result showed the presence of bronchiectasis and its severity were still independently associated with increased mortality of COPD adjusted for confounding variables (see Supplementary Table A3, Supplementary Table A4).

**Characteristics of comorbid bronchiectasis patients**

Among 318 COPD patients with bronchiectasis patients, 259 (81.4%) patients showed cylindrical bronchiectasis, 59 (18.6%) showed cystic/varicose bronchiectasis.

Table 5 showed comorbid cystic/varicose bronchiectasis patients had more *Pseudomonas aeruginosa* isolates compared with comorbid cylindrical bronchiectasis patients (p=0.017). 272 COPD patients with bronchiectasis completed the follow-up, 112 (41.2%) patients died during the follow-up period. Figure 3 showed Kaplan-Meier curves separated significantly among COPD without bronchiectasis, comorbid cystic/varicose bronchiectasis, comorbid cylindrical bronchiectasis groups (log-rank test 18.201, p<0.001). Multivariate Cox’s proportional hazard regression analysis showed comorbid cystic/varicose bronchiectasis patients presented worse prognostic risk compared with cylindrical bronchiectasis patients (HR 1.683, 95% CI 1.084-2.612, p=0.020) (see Table 6).

Bronchiectasis associated with COPD is rarely cystic/varicose type. To minimize the possibility that radiological bronchiectasis was secondary to primary bronchiectasis with airflow obstruction rather
than associated with COPD, Cox regression analysis was repeatedly evaluated after excluding COPD patients with severe bronchiectasis (cystic/varicose). Multivariate Cox regression analysis showed the presence of cylindrical bronchiectasis was still independently associated with increased mortality of COPD patients (HR 1.426, 95%CI, 1.064-1.910, p=0.017) after adjusted for confounding variables (see Supplementary Table A5).

Discussion

Our study subjects were based on inpatients with COPD exacerbation, which was different from the previous studies from stable COPD patients. Our findings predicted that the presence of bronchiectasis and its severity were independently associated with all-cause mortality in patients with COPD exacerbation. Meanwhile, further analysis revealed the presence of cystic/varicose bronchiectasis predicted worse prognosis of COPD patients than that of cylindrical bronchiectasis, which was the first study showing the relationship between different types of bronchiectasis and mortality of COPD patients.

A high proportion of radiological bronchiectasis in COPD patients in our study was 42.5%. Although there were no studies which had definitely reported the causal relationship between COPD and bronchiectasis, the point was suspected by the condition: the previous study reported up to 40% COPD patients had high risk of a large number of meaningful bacterial colonization, especially in patients with a higher degree of airway obstruction [27]. This situation impairs host defense mechanisms [28], subsequently increases airway inflammation reaction and progressive lung structural damage, which is a vicious cycle and provides a base for formation of bronchiectasis. In our study, identification of bronchiectasis in COPD patients was associated with some worse functional and physiological parameters in COPD patients, which were in agreement with previous studies [10, 11, 13, 15]. These findings predicted comorbid bronchiectasis patients might have worse prognosis.

During the long-term follow-up period, COPD patients with bronchiectasis showed a higher mortality than those without bronchiectasis. However, there was no significant difference in mortality within 2 years. This point may be suspected by this condition: increasing exacerbation frequency is associated with higher mortality and exacerbations in the previous year is the single best predictor of future
exacerbations [29-30]. The previous study reported the presence of bronchiectasis was associated with frequent exacerbation or hospitalization [12], which may predict comorbid bronchiectasis. Patients have frequent future exacerbations and subsequently increased bronchiectasis extent, furtherly resulted in an increased risk in long-term mortality of COPD. Otherwise, it may also be associated with a relatively low in mortality of COPD within 2 years. This is only a guess and needs to be confirmed by further research. Meanwhile, our data showed the presence of bronchiectasis was independently associated with all-cause mortality of COPD adjusted for other variables, which was consistent with the studies of Martinez Garcia et al and Mao et al and contrary to another two studies from Gatheral and Jairam et al [11, 13, 7, 21]. The discordance could be explained by difference in study design. The first two studies were mainly concerned with the presence of bronchiectasis considered as a dichotomous variable, while the latter two studies were concerned with severity of bronchiectasis. When using quantitative variable “Smith score” of bronchiectasis instead of the dichotomous variable “presence of bronchiectasis”, this result was also confirmed. In view of our study subjects who were patients of severe exacerbation of COPD, early death may be associated with this acute exacerbation of COPD. Therefore, further analysis was performed after excluding patients who died in hospital and within 90 days after discharge, which revealed bronchiectasis was still independently associated with increased all-cause mortality of COPD patients, furtherly confirmed radiological bronchiectasis in COPD patients could be used as a new and distinct clinical phenotype [31], mainly affected the long-term survival of COPD patients.

In our study, comorbid radiological bronchiectasis in COPD patients was mainly cylindrical type. In the previous study, the presence of cystic/varicose bronchiectasis in COPD patients presented more clinical symptoms, more severe lung function than cylindrical bronchiectasis and was associated with bacterial colonization [32]. In our study, comorbid cystic/varicose bronchiectasis patients presented higher Pseudomonas aeruginosa isolates compared with cylindrical bronchiectasis patients. Because Pseudomonas aeruginosa isolates [6, 33], severe lung function may be associated with increased mortality in COPD patients [34], we suspected whether cystic/varicose bronchiectasis predicted worse prognosis in COPD patients. Our data revealed COPD patients without bronchiectasis presented the
best prognosis, while comorbid cystic/varicose bronchiectasis patients presented the worst prognosis, the prognosis of comorbid cylindrical bronchiectasis patients lay between two groups. Furthermore, we perceived the presence of cystic/varicose bronchiectasis was independently associated with an increased risk of death of COPD patients with bronchiectasis. In order to minimize the possibility that the presence of bronchiectasis was mainly from primary bronchiectasis with airflow obstruction rather than secondary to COPD, our further analysis was performed and the data result revealed that the presence of cylindrical bronchiectasis was still a prognostic risk factor for mortality of COPD after excluding comorbid cystic/varicose bronchiectasis patients. These studies furtherly confirmed comorbid bronchiectasis especially cystic/varicose bronchiectasis predicted worse prognosis of COPD patients.

This study has several limitations. Firstly, due to nature of the retrospective study, some variables which may affect prognosis of COPD patients such as lung function and body mass index have more missing data, therefore, they were not included in survival analysis. Secondly, it was still difficult to distinguish whether bronchiectasis was associated with COPD especially comorbid severe bronchiectasis after excluding some known causes of secondary bronchiectasis. Finally, some data with regard to management of COPD patients in follow-up period such as lung rehabilitation and medicine usage such as antibiotics and vaccination were not included in survival analysis. These factors may influence our results analysis.

In summary, based on the current study, the presence and the severity of bronchiectasis were independently associated with prognosis of COPD patients. In addition, another significant discovery was that the presence of varicose/cystic bronchiectasis predicted worse prognosis of COPD than that of cylindrical bronchiectasis. Furtherly rigorous and large-scale prospective studies are needed to affirmed causal relationship between bronchiectasis and COPD and the prognostic influence of bronchiectasis on COPD patients.

List Of Abbreviations
COPD, Chronic Obstructive Pulmonary Disease; HRCT, high-resolution computed tomography; HR, hazard ratio; CI, confidence interval; PPMs, potential pathogenic microorganisms.
Declarations

Acknowledgements

Not applicable.

Funding

This work was supported by National Key R&D Program of China (2016YFC1303900); the Beijing Municipal Administration of Hospitals’ Mission Plan, China (No. SML20150301); Capital’s Funds for Health Improvement and Research (No. CFH2016-4-1062) and Chinese Medical Association Chronic Respiratory Disease Fund (No. CRD 08020440122).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Y.Z participated in the design of the study, performed the experiments, data analysis, and drafted manuscript. Y.L.G evaluated and interpreted radiological bronchiectasis. H.Z.S, Y.X.L designed the study and supervised the experimental work, analyzed the result and revised the manuscript. S.Z, Z.W, X.N.B, K.W.H participated in reviewing and revised the manuscript. All authors reviewed the manuscript.

Ethics approval and consent to participate

The research scheme was approved by the ethics committee of Beijing Chao-Yang Hospital (IRB No.2017-23). Informed consent from patients was not required by the committee because this study was the non-interventional, observational design of the protocol and posed no risk or harm to the subjects included in the study.

Consent for publication

Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931. doi:10.1136/thx.2005.040527.

2. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest. 2007;132(6):1748-1755. doi:10.1378/chest.06-3018.

3. Mendy A, Forno E, Niyonsenga T, Gasana J. Blood Biomarkers as Predictors of Long-Term Mortality in COPD. Clin Respir J. 2018;12(5):1891-1899. doi:10.1111/crj.12752.

4. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68(7):670-676. doi:10.1136/thoraxjnl-2012-201871.

5. Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, Castro-Acosta A, Studnicka M, Kaiser B, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016;47(1):113-121. doi:10.1183/13993003.01391-2014.

6. Almagro P, Salvadó M, Garcia-Vidal C, Rodríguez-Carballeira M, Cuchi E, Torres J, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration. 2012;84(1):36-43. doi:10.1159/000331224.

7. Gatheral T, Kumar N, Sansom B, Lai D, Nair A, Vlahos I, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD. 2014;11(6):605-614. doi:10.3109/15412555.2014.922174.

8. O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55(8):635-642.

9. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400-407. doi:10.1164/rccm.200305-648OC.
10. Martínez-García MÁ, Soler-Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130-1137. doi:10.1378/chest.10-1758.

11. Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, Donat-Sanz Y, Serra PC, Lerma MA, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823-831. doi:10.1164/rccm.201208-1518OC.

12. Kawamatawong T, Onnipa J, Suwatanapongched T. Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients. Int J Chron Obstruct Pulmon Dis. 2018; 13:761-769. doi:10.2147/COPD.S139776.

13. Mao B, Lu HW, Li MH, Fan LC, Yang JW, Miao XY, et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci Rep. 2015; 5:10691. doi:10.1038/srep10961.

14. Bafadhel M, Umar I, Gupta S, Raj JV, Vara DD, Entwisle JJ, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest. 2011;140(3):634-642. doi:10.1378/chest.10-3007.

15. Jin J, Yu W, Li S, Lu L, Liu X, Sun Y. Factors associated with bronchiectasis in patients with moderate-severe chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95(29): e4219. doi:10.1097/MD.0000000000004219.

16. Dou S, Zheng C, Cui L, Xie M, Wang W, Tian H, et al. High prevalence of bronchiectasis in emphysema-predominant COPD patients. Int J Chron Obstruct Pulmon Dis. 2018; 13:2041-2047. doi:10.2147/COPD.S163243.

17. Dou S, Zheng C, Ji X, Wang W, Xie M, Cui L, et al. Co-existence of COPD and bronchiectasis: a risk factor for a high ratio of main pulmonary artery to aorta diameter (PA: A) from computed tomography in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018; 13:675-681. doi:10.2147/COPD.S156126.

18. Bak SH, Kim S, Hong Y, Heo J, Lim MN, Kim WJ. Quantitative computed tomography features and clinical manifestations associated with the extent of bronchiectasis in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13:1421-1431. doi: 10.2147/COPD.S157953.

19. Stratev V, Petkova D, Dimitrova V, Petev J. Comorbidities of COPD in Bulgarian Patients -
Prevalence and Association with Severity and Inflammation. Folia Med (Plovdiv). 2018;60(1):102-109. doi:10.1515/folmed-2017-0078.

20. Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015; 10:1465-1475. doi:10.2147/COPD.S83910.

21. Jairam PM, van der Graaf Y, Lammers JW, Mali WP, de Jong PA. Incidental findings on chest CT imaging are associated with increased COPD exacerbations and mortality. Thorax. 2015;70(8):725-731. doi:10.1136/thoraxjnl-2014-206160.

22. Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM, Flower CD. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax. 1996;51(9):914-918. PMID:8984702.

23. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557-582. doi:10.1164/rccm.201701-0218PP.

24. Naidich DP, McCauley DI, Khouri NF, Stitik FP, Siegelman SS. Computed tomography of bronchiectasis. J Comput Assist Tomogr. 1982;6(3):437-444. PMID:7096687.

25. Lynch DA, Newell JD, Tschomper BA, Cink TM, Newman LS, Bethel R. Uncomplicated asthma in adults: comparison of CT appearance of the lungs in asthmatic and healthy subjects. Radiology. 1993;188(3):829-833. doi:10.1148/radiology.188.3.8351357.

26. Tan WC, Hague CJ, Leipsic J, Bourbeau J, Zheng L, Li PZ, et al. Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. PLoS One. 2016;11(11): e0166745. doi:10.1371/journal.pone.0166745.

27. Zalacain R, Sobradillo V, Amilibia J, Barrón J, Achótegui V, Pijoan JI, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J. 1999;13(2):343-348. PMID:10065679.
28. Jansen HM, Sachs AP, van Alphen L. Predisposing conditions to bacterial infections in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151(6):2073-2080. doi:10.1164/ajrccm.151.6.7767560.

29. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005 Nov;60(11):925-931. doi:10.1136/thx.2005.040527.

30. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16;363(12):1128-1138. doi:10.1056/NEJMoa0909883.

31. O'Donnell AE. Bronchiectasis in patients with COPD: a distinct COPD phenotype? Chest. 2011;140(5):1107-1108. doi:10.1378/chest.11-1484.

32. Angrill J, Agustí C, De Celis R, Rañó A, Gonzalez J, Solé T, Xaubet A, Rodriguez-Roisin R, Torres A. Bacterial colonization in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57(1):15-19. PMID:11809984.

33. Rodrigo-Troyano A, Suarez-Cuartin G, Peiró M, Barril S, Castillo D, Sanchez-Reus F, et al. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology. 2016;21(7):1235-1242. doi:10.1111/resp.12825.

34. Mekov E, Slavova Y, Tsakova A, Genova MP, Kostadinov DT, Minchev D, et al. One-year mortality after severe COPD exacerbation in Bulgaria. PeerJ. 2016 Dec 13;4:e2788. doi:10.7717/peerj.2788.

Tables

Table 1 Baseline and clinical characteristics of COPD subjects with and without bronchiectasis

| Parameter                        | Whole Group | COPD with bronchiectasis | COPD without bronchiectasis | p-value |
|----------------------------------|-------------|--------------------------|-----------------------------|---------|
| Subjects, n (%)                  | 748(100)    | 318(42.5)                | 430(57.5)                   | —       |
| Male, n (%)                      | 550(73.5)   | 246 (77.4)               | 304 (70.7)                  | 0.041   |
| Age, y                           | 73.06±9.34  | 73.23±9.36               | 72.93±9.33                  | 0.736   |
| Body mass index, kg/m²           | 23.27±4.55  | 22.74±4.58               | 23.68±4.49                  | 0.011   |
| Comparison                          | Group 1          | Group 2          | Group 3          | p-value  |
|------------------------------------|------------------|------------------|------------------|----------|
| Smoking history, n (%)             | 587 (78.5)       | 249 (78.3)       | 338 (78.6)       | 0.921    |
| Pack-years smoked                  | 41.31±29.21      | 38.75±25.36      | 43.20±31.66      | 0.273    |
| Time since onset of symptoms, y    | 16.53±13.43      | 17.43±13.48      | 15.86±13.37      | 0.051    |
| Daily expectoration, n (%)         | 698 (93.3)       | 299 (94.0)       | 399 (92.8)       | 0.504    |
| History of dyspnea, y              | 12.09±12.09      | 13.12±12.31      | 11.32±11.88      | 0.022    |
| Ischemic heart disease, n (%)      | 172 (23.0)       | 65 (20.4)        | 107 (24.9)       | 0.153    |
| Arrhythmias, n (%)                 | 54 (7.2)         | 19 (6)           | 35 (8.1)         | 0.258    |
| Heart failure, n (%)               | 80 (10.7)        | 27 (8.5)         | 53 (12.3)        | 0.093    |
| Previous tuberculosis, n (%)       | 69 (9.2)         | 36 (11.3)        | 33 (7.7)         | 0.088    |
| Pulmonary heart disease, n (%)     | 262 (35.0)       | 118 (37.1)       | 144 (33.5)       | 0.305    |
| Hospital admission in the previous year, n (%) | 231 (30.9) | 100 (31.4) | 131 (30.5) | 0.774 |
| Length of hospitalization, d       | 10.41±4.69       | 10.63±5.06       | 10.25±4.39       | 0.590    |
| Albumin, mg/dL                     | 32.99±4.40       | 32.92±4.52       | 33.04±4.31       | 0.799    |
| fibrinogen                         | 345.14±110.451   | 357.69±108.68    | 335.84±110.96    | 0.005    |
| Hemoglobin g/L                     | 134.19±21.42     | 134.10±21.86     | 134.26±21.12     | 0.926    |
| Patients with PPMs isolates, n (%) | 83 (11.1)        | 38 (11.9)        | 45 (10.5)        | 0.523    |
| Pseudomonas aeruginosa isolates, n (%) | 36 (4.8)  | 21 (6.6)         | 15 (3.5)         | 0.049    |
Notes: Data are presented as number (%) or mean±SD unless specified.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; PPMs, potential pathogenic microorganisms.

Table 2 Baseline pulmonary function of COPD subjects with and without bronchiectasis
| Parameter                          | Whole Group | COPD with bronchiectasis | COPD without bronchiectasis | p-value |
|-----------------------------------|-------------|--------------------------|-----------------------------|---------|
| Subjects*                         | 306(100)    | 123(40.2)                | 183(59.8)                   | —       |
| Postbronchodilator FEV1(L)        | 1.11±0.41   | 1.06±0.38                | 1.15±0.42                   | 0.058   |
| Predicted %                       | 47.28±17.94 | 44.25±16.6               | 49.32±18.55                 | 0.013   |
| Post-bronchodilator FVC (ml)      | 2.37±0.63   | 2.37±0.63                | 2.37±0.63                   | 0.75    |
| Predicted %                       | 77.36±19.36 | 75.89±20.86              | 78.34±18.29                 | 0.135   |
| FEV1/FVC % predicted              | 46.52±9.72  | 44.52±9.04               | 47.87±9.95                  | 0.003   |

Notes: Data are presented as number (%) or mean±SD unless specified.

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

*The total number of lung functions available for data analysis was 306. The total number of comorbid bronchiectasis patients with lung functions available was 123, the total number of non-bronchiectasis patients with lung function available was 183.
Table 3 Association between the presence of bronchiectasis and death of COPD

| Variables                                   | Unadjusted HR [95% CI] | p-value | Fully Adjusted HR (95% CI) | p-value |
|---------------------------------------------|-------------------------|---------|-----------------------------|---------|
| Age                                         | 1.052 (1.034-1.069)     | <0.001  | 1.047 (1.030-1.065)         | <0.001  |
| Length of hospitalization                   | 1.035 (1.023-1.047)     | <0.001  | 1.026 (1.008-1.043)         | 0.003   |
| Albumin                                     | 0.938 (0.91-0.968)      | <0.001  | 0.949 (0.919-0.980)         | 0.001   |
| Hospital admission in the previous year     | 1.696 (1.288-2.234)     | <0.001  | 1.487 (1.119-1.977)         | 0.006   |
| Bronchiectasis                              | 1.580 (1.204-2.072)     | 0.001   | 1.504 (1.144-1.978)         | 0.003   |
| Pulmonary heart disease                     | 1.764 (1.345-2.312)     | <0.001  | 1.472 (1.113-1.946)         | 0.007   |

Abbreviations: HR, hazard ratio; CI, confidence interval.

Table 4 Association between bronchiectasis total score and death of COPD
| Variables                                           | Unadjusted HR| 95%CI    | p-value  | Fully Adjusted HR| 95%CI    | p-value  |
|----------------------------------------------------|--------------|----------|----------|------------------|----------|----------|
| Age                                                | 1.052        | (1.034-1.069) | <0.001   | 1.048            | (1.030-1.065) | <0.001   |
| Length of hospitalization                          | 1.035        | (1.023-1.047) | <0.001   | 1.027            | (1.009-1.045) | 0.002    |
| Albumin                                            | 0.938        | (0.91-0.968)   | <0.001   | 0.951            | (0.921-0.982) | 0.002    |
| Hospital admission in the previous year            | 1.696        | (1.288-2.234)  | <0.001   | 1.501            | (1.130-1.992) | 0.005    |
| Bronchiectasis total score                         | 1.062        | (1.011-1.115)  | 0.016    | 1.058            | (1.007-1.112) | 0.026    |
| Pulmonary heart disease                            | 1.764        | (1.345-2.312)  | <0.001   | 1.492            | (1.129-1.972) | 0.005    |

Abbreviations: HR, hazard ratio; CI, confidence interval.
Table 5 Clinical Characteristic of COPD subjects with bronchiectasis according to the types of bronchiectasis

| Parameter                                      | Whole group | Cystic/Varicose bronchiectasis | Cylindrical bronchiectasis | p-value |
|-----------------------------------------------|-------------|---------------------------------|-----------------------------|---------|
| Subjects                                      | 318 (100)   | 59 (18.6)                       | 259 (81.4)                  | ——      |
| Age, y                                        | 73.23±9.36  | 72.9±9.44                       | 73.31±9.36                  | 0.682   |
| Male, n(%)                                    | 246(77.4)   | 47(79.7)                        | 199(76.8)                   | 0.640   |
| Body mass index, kg/m²                        | 22.74±4.58  | 23.06±4.11                      | 22.68±4.67                  | 0.606   |
| Smoking history, n(%)                         | 249 (78.3)  | 43 (72.9)                       | 206 (79.5)                  | 0.263   |
| Pack-years smoked                             | 38.77±25.41 | 37.95±27.07                     | 38.94±25.11                 | 0.615   |
| Time since onset of symptoms, y               | 17.43±13.48 | 19.42±14.41                     | 16.97±13.25                 | 0.282   |
| History of dyspnea, y                         | 13.12±12.31 | 14.40±13.62                     | 12.84±12.00                 | 0.529   |
| Previous tuberculosis, n (%)                  | 36 (11.3)   | 5 (8.5)                         | 31 (12.0)                   | 0.445   |
| Ischemic heart disease, n (%)                 | 65(20.4)    | 10(16.9)                        | 55(21.2)                    | 0.461   |
| Arrhythmias, n (%)                            | 19(6.0)     | 3(5.1)                          | 16(6.2)                     | 0.749   |
| Heart failure, n (%)                          | 27(8.5)     | 3(5.1)                          | 24(9.3)                     | 0.298   |
| Pulmonary heart disease, n (%)                | 118(37.1)   | 22(37.3)                        | 96(37.1)                    | 0.975   |
| Hospital admission in the previous year, n (%)| 100 (31.4)  | 23 (39)                         | 77(29.7)                    | 0.167   |
| Length of hospitalization, d                  | 10.63±5.06  | 11.81±6.93                      | 10.37±4.51                  | 0.195   |
| Albumin, mg/dL                                | 32.92±4.52  | 31.92±5.37                      | 33.15±4.28                  | 0.115   |
| Fibrinogen                                    | 357.69±108.68 | 337.61±106.64                 | 362.16±108.83              | 0.072   |
### Table 6: Association between the types of bronchiectasis and death of COPD patients with bronchiectasis

|                          | 134.10±21.86 | 132.41±26.15 | 134.48±20.79 | 0.650 |
|--------------------------|--------------|--------------|--------------|-------|
| Patients with PPMs isolates, n (%) | 38 (11.9)    | 8 (13.6)     | 30 (11.6)    | 0.673 |
| *Pseudomonas aeruginosa* isolates, n (%) | 21 (6.6) | 8 (13.6) | 13 (5.0) | 0.017 |
| All-cause mortality*, n (%) | 112 (41.2) | 28 (53.8) | 84 (38.2) | 0.039 |

Notes: Data are presented as number (%) or mean±SD unless specified.

*A total of 272 patients with chronic obstructive pulmonary disease associated with bronchiectasis were followed up, 112 of whom died during the study.

Abbreviations: PPMs, potential pathogenic microorganisms.
| Variables                        | Unadjusted                  | Fully Adjusted                   |
|---------------------------------|-----------------------------|----------------------------------|
|                                 | HR (95%CI)                  | HR (95%CI)                       | p-value | p-value |
| Age                             | 1.049 (1.027-1.072)         | 1.046 (1.023-1.069)              | 0.001   | <0.001  |
| Length of hospitalization       | 1.034 (1.021-1.048)         | 1.028 (1.013-1.044)              | 0.001   | <0.001  |
| Bronchiectasis type             | 1.680 (1.094-2.581)         | 1.683 (1.084-2.612)              | 0.018   | 0.020   |
| Previous tuberculosis tuberculosis | 1.623 (0.968-2.720)         | 1.691 (1.006-2.844)              | 0.066   | 0.048   |
| Pulmonary heart disease         | 1.768 (1.220-2.562)         | 1.632 (1.118-2.384)              | 0.003   | 0.011   |

Abbreviations: HR, hazard ratio; CI, confidence interval.

Figures

![Figure 1](image1)

**Figure 1**
Total bronchiectasis score

![Figure 2](image2)

**Figure 2**
Kaplan-Maier survival curves between COPD patients with and without bronchiectasis groups

(log-rank test 11.201, p=0.001).

![Figure 3](image3)

**Figure 3**
Kaplan-Maier survival curves among non-bronchiectasis and cystic/varicose bronchiectasis and cylindrical bronchiectasis groups (log-rank test 18.201, p<0.001).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

Supplementary Tables.docx
